ABOUT PARSE BIOSCIENCES

Imagine your science more powerful than ever

At Parse Biosciences, we are propelling single cell science forward with constant innovation. We’re driven to deliver researchers new capabilities that push the limits of what’s possible.

Our relentless drive to expand the boundaries of single cell science is fueled by a desire to help you unlock the workings of biology. We share your hunger to constantly learn, discover, and expand the body of knowledge in human health and science.

Pioneering new research across all areas of biology

Single cell sequencing is enabling breakthroughs in developmental biology, stem cell therapy, immunotherapy, our understanding of COVID-19, and treatments in neurology, diabetes, vascular injury and disease, and cancer. New areas of inquiry are constantly unfolding, and Parse will continue supporting the trailblazing researchers that are leading the way.

Built on a foundation of groundbreaking science, Parse Biosciences is setting a course of rapid innovation.

Leadership

CEO and Cofounder

Alex Rosenberg, PhD

Alex cofounded Parse Biosciences and leads the organization as its Chief Executive Officer. Alex is an experienced leader and technologist with a track record of pushing innovation in next-generation sequencing, machine learning, and predictive models of biology. As a Commercialization Fellow at the University of Washington, Alex co-invented the single cell technology that inspired Parse’s foundational Evercode™ platform. Alex is an active technical leader and inventor, with multiple publications in high-profile journals, such as Cell and Science, and several patents.

Alex received a PhD in Electrical Engineering from the University of Washington and a BSE in Electrical Engineering from the University of Michigan.

CTO and Cofounder

Charlie Roco, PhD

Charlie cofounded Parse Biosciences and leads as its Chief Technology Officer. Charlie is passionate about biology-based technology development, with over a decade of driving innovation in the field. Prior to Parse, he studied at the University of Washington, where he received several fellowships from the National Institutes of Health and Fred Hutch Cancer Research Center. This work generated high-profile publications in Science and informed the core technology of Parse Biosciences. Previously, Charlie contributed to innovations in drug delivery and microscopy at the Wyss Institute at Harvard and the University of Pennsylvania.

Charlie received a PhD in Bioengineering from the University of Washington and a BSE in Biological Systems Engineering from Virginia Tech.

Whole Transcriptome

Immune Profiling

Additional Capabilities

Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei

Parse Launches GigaLab to Scale Single Cell Sequencing to Billions of Cells Annually

Technology

The end-to-end solution

Products